All stock lists
NovaBridge Biosciences (NASDAQ:NBP)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.37+0.04 (+3.01%)
Insider Score
––Not scored
NBP Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
NBP analyst forecast
NBP analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
NBP 12-month price target
No published price targets in the last 12 months.
Best analysts covering NBP
- HC Wainwright & Co.0%success rate · 7 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
NBP analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-04-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-02-06 |
| — | BTIG | Buy | — | — | Reiterated | 2025-10-24 |
| — | BTIG | Buy | — | — | Reiterated | 2025-10-17 |
| — | BTIG | Buy | — | — | Reiterated | 2025-09-10 |
| — | Needham | Buy | — | — | Reiterated | 2025-09-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-08-21 |
| — | Needham | Buy | — | — | Reiterated | 2025-08-20 |
| — | Needham | Buy | — | — | Reiterated | 2025-07-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-07-09 |
| — | Needham | Buy | — | — | Reiterated | 2025-06-27 |
| — | Needham | Buy | — | — | Reiterated | 2023-09-24 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-09-04 |
| — | Needham | Buy | — | — | Reiterated | 2023-08-17 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2023-08-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-17 |
| — | Needham | Buy | — | — | Reiterated | 2023-06-04 |
| — | Needham | Buy | — | — | Reiterated | 2023-04-19 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-04-02 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2023-04-02 |
| — | Needham | Buy | — | — | Reiterated | 2023-04-02 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-08-30 |
| — | Needham | Buy | — | — | Reiterated | 2022-08-30 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2022-08-29 |
| — | Needham | Buy | — | — | Reiterated | 2022-08-16 |
| — | Needham | Buy | — | — | Reiterated | 2022-05-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-05-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-03-29 |
| — | Needham | Buy | — | — | Reiterated | 2021-10-31 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-08-31 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2021-06-09 |
| — | Daiwa Capital | Buy | — | — | Reiterated | 2021-06-02 |
| — | Needham | Buy | — | — | Reiterated | 2021-03-15 |
| — | H.C. Wainwright | Buy | — | — | Reiterated | 2021-03-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-03-02 |
| — | H.C. Wainwright | Buy | — | — | Reiterated | 2021-03-02 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2021-02-25 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2020-12-07 |
| — | CMB International | Buy | — | — | Reiterated | 2020-08-26 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2020-07-27 |
| — | CICC | Outperform | — | — | Reiterated | 2020-02-14 |
| — | China Renaissance | Buy | — | — | Reiterated | 2020-02-12 |
| — | Jefferies | Buy | — | — | Reiterated | 2020-02-11 |
NBP earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-07-30 | -0.01 | -0.22 | $0 | $0 |
| 2026-08-20 | -0.03 | -0.02 | $0 | $0 |
| 2026-11-12 | -0.08 | 0.00 | $33.6M | $0 |
| 2027-03-31 | -0.03 | 0.00 | $17.5M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.